Biora-tm_rgb.jpg
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
August 12, 2024 16:15 ET | Biora Therapeutics, Inc.
Phase 1 clinical trial results for BT-600 demonstrate precise drug delivery to the colon with low systemic exposure, supporting clinical development plan Company secures up to $16M funding from...
Biora-tm_rgb.jpg
Biora Therapeutics Announces Funding Agreement with Existing Investors
August 12, 2024 16:05 ET | Biora Therapeutics, Inc.
$16 million multiple-draw facility to be used as a bridge to anticipated pharma partnership
Biora-tm_rgb.jpg
Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update
August 08, 2024 16:30 ET | Biora Therapeutics, Inc.
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and...
Biora-tm_rgb.jpg
Biora Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference
August 06, 2024 08:00 ET | Biora Therapeutics, Inc.
SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that company leadership will participate...
Biora-tm_rgb.jpg
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
July 18, 2024 08:00 ET | Biora Therapeutics, Inc.
Pharmacokinetic and tissue data confirm NaviCap platform delivers topically through the entire colon, with lower systemic concentrations, as desired.
Biora-tm_rgb.jpg
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
July 08, 2024 08:00 ET | Biora Therapeutics, Inc.
Event to highlight results from the clinical trial of BT-600, an orally administered drug-device combination in development for ulcerative colitis.
Biora-tm_rgb.jpg
Biora Therapeutics Announces Positive Clinical Trial Results for BT-600
July 01, 2024 08:00 ET | Biora Therapeutics, Inc.
BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform’s ability to deliver therapeutics directly to the colon
Biora-tm_rgb.jpg
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024
June 11, 2024 08:00 ET | Biora Therapeutics, Inc.
Biora will present preclinical data from the BioJet™ Systemic Oral Delivery Platform at the conference on June 19, 2024.
Biora-tm_rgb.jpg
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
May 20, 2024 08:00 ET | Biora Therapeutics, Inc.
Four device performance studies demonstrate the NaviCap platform’s ability to deliver therapeutics directly to the colon under variable GI conditions.
Biora-tm_rgb.jpg
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 15, 2024 16:05 ET | Biora Therapeutics, Inc.
Management will host conference call and webcast today, May 15, 2024, at 4:30 PM Eastern / 1:30 PM Pacific.